An interventional study of T cell injection targeting CD7 chimeric antigen receptor in Systemic Sclerosis - 2013 ACR/EULAR Classification Criteria, sponsored by PersonGen BioTherapeutics (Suzhou) Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-03-12.
Sponsored by PersonGen BioTherapeutics (Suzhou) Co., Ltd. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 82 studies in Scleroderma, Systemic with a site in China — 64 open to participants now, 69 under way, 4 of them phase 3. Scleroderma, Systemic · China.
Among the 82 studies in Scleroderma, Systemic with a site in China, this one is the 41st largest by planned enrollment of the 77 interventional ones that give a count, is one of 29 that started in 2025, is one of 15 with no phase, reaches primary completion later than 13 of the 68 other live ones, and was the 38th registered.
614 studies on the registry are indexed under Scleroderma, Systemic; 222 are open to participants now.
Browse Scleroderma, Systemic studies →64 of the 82 studies in Scleroderma, Systemic with a site in China are open now. Recruiting first, the newest first:
Antengene Biologics Limited · Sites in China
Ages 18+
AstraZeneca · Sites in China, United States, Argentina and 32 more countries
Ages 5–80
Boehringer Ingelheim · Sites in China, United States, Argentina and 42 more countries
Ages 18+
Peking University Third Hospital · Sites in China
Ages 18+
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18–70
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 146 Scleroderma, Systemic studies recruiting now, 84 (58%) set no upper age limit and 49 (34%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
82 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 47 · Phase 2 13 · Phase 3 7 · Phase 4 4
First in 2008; this study’s year is marked. 29 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 18 is below the median of 37 across 450 interventional studies indexed under Scleroderma, Systemic.
Median enrollment 20 across the 77 interventional studies, 490 across the 5 observational. Of the 3 that completed or were terminated, 1 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 82 have an industry lead sponsor. The 10 most frequent:
PersonGen BioTherapeutics (Suzhou) Co., Ltd. is the lead sponsor of 43 studies on the registry; 17 are open to participants now.
PersonGen BioTherapeutics (Suzhou) Co., Ltd. has 5 studies filed under Scleroderma, Systemic — fewer than ten, so there is no comparison to draw.
17 of the studies in Scleroderma, Systemic with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05925803Phase 3AstraZenecaDetermine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY) | 2027-01-06 |
| NCT06822881Beijing GoBroad HospitalCT1190B in the Treatment of Patients With Moderate to Severe Refractory Systemic Lupus Erythematosus (SLE) or Refractory/Progressive Systemic Sclerosis (SSc) | 2026-12-31 |
| NCT06548607Nanjing Bioheng Biotech Co., Ltd.Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases | 2026-12-31 |
| NCT07641634Prolium Bioscience, IncA Phase 1/2 Study of PRO-203 in Healthy Volunteers and Participants With Systemic Sclerosis. | 2027-01 |
| NCT06775912Nanjing Bioheng Biotech Co., Ltd.Clinical Study on Targeted CD19/BCMA CAR-T Therapy for Autoimmune Diseases | 2027-01-01 |
Add all 17 to your calendar (.ics) → With an account.
Among the 82 studies in Scleroderma, Systemic with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective was to evaluate the safety of CD7 CAR-T cells for the treatment of subjects with relapsed/refractory AID. CD7 CAR-T cells were infused in a single infusion in subjects who were screened after signing an informed consent form and undergoing single nucleus cell collection and pretreatment, and blood was collected before and after the infusion for pharmacokinetic, pharmacodynamic, immunogenicity, and safety evaluations.
Subjects who meet the inclusion/exclusion criteria will be entered into 3 groups in sequential order for a single dose. The dose-escalation study utilizes a "3+3" design, i.e., 3-6 subjects in each group will complete a single dose.
After the last subject in each dose group completes a dose-limiting toxicity (DLT) assessment window of 28 days after the single dose, enrollment in the next dose group can begin.
When 1 DLT occurs in 3 subjects in a dose group, 3 additional subjects are required in the same dose group (up to 6 subjects in that dose group have completed DLT assessment): if no DLT occurs in the 3 additional subjects, continue the dose escalation; if 1 of the 3 additional subjects develops a DLT, stop the dose escalation; if >1 of the 3 additional subjects DLT occurs, the dose escalation is stopped and a one-dose reduction is required to continue enrolling 3 more subjects for DLT assessment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Bone marrow and coagulation function, liver and kidney function, cardiopulmonary function are satisfied No serious mental disorders
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD7 CAR-T cell therapy Subjects meeting the inclusion/exclusion criteria will be entered into the 0.25×108, 1×108, and 2×108 CAR-T groups in sequential order, and will be administered once
Biological: T cell injection targeting CD7 chimeric antigen receptor
Subjects who sign the informed consent form and meet the inclusion/exclusion criteria will be entered into the 0.25×108, 1×108 and 2×108 CAR-T groups, in order of priority, and will be administered 1 dose of
adverse events
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
Time frame: About 1 year
(Cmax)
Maximum concentration of CD7 CAR-T cells expanded in peripheral blood after drug administration
Time frame: About 1 year
(Tmax)
Time to maximum concentration
Time frame: About 1 year
AUC0-28d
Area under the curve at 28 days
Time frame: About 28 days
AUC0-90d
Area under the curve at 90 days
Time frame: About 90 days
Disease remission rate
Rate of decline from baseline in the American College of Rheumatology Composite Response Index (ACR-CRISS)
Time frame: About 90 days
Plan to share: Yes — Research details
No publications or documents are linked to this record.
Start is estimated for Mar 2025; primary completion for Mar 2026, 12 months later.
Of 101 interventional studies with no phase under Scleroderma, Systemic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 38. This study's planned 12 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Autologous Anti-CD7 CAR T Cells PA3-17
PersonGen BioTherapeutics (Suzhou) Co., Ltd. →